Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Edwards Lifesciences Corp (NYSE: EW) was $84.30 for the day, down -0.44% from the previous closing price of $84.67. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 2.2 million shares were traded. EW stock price reached its highest trading level at $85.7 during the session, while it also had its lowest trading level at $83.5.
Ratios:
Our analysis of EW’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 29.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 187.17. For the most recent quarter (mrq), Quick Ratio is recorded 2.67 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
On February 02, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $94.
Evercore ISI Downgraded its Outperform to In-line on January 04, 2024, whereas the target price for the stock was revised from $80 to $77.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 01 ’24 when Lemercier Jean-Luc M sold 14,400 shares for $84.21 per share. The transaction valued at 1,212,687 led to the insider holds 173,849 shares of the business.
Ullem Scott B. sold 7,250 shares of EW for $622,062 on Apr 30 ’24. The CVP, Chief Financial Officer now owns 19,074 shares after completing the transaction at $85.80 per share. On Apr 09 ’24, another insider, Lippis Daniel J., who serves as the CVP, JAPAC of the company, sold 857 shares for $92.34 each. As a result, the insider received 79,135 and left with 17,488 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 50799181824 and an Enterprise Value of 49784979456. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 36.23, and their Forward P/E ratio for the next fiscal year is 27.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.27 while its Price-to-Book (P/B) ratio in mrq is 7.13. Its current Enterprise Value per Revenue stands at 8.104 whereas that against EBITDA is 25.959.
Stock Price History:
Over the past 52 weeks, EW has reached a high of $96.12, while it has fallen to a 52-week low of $60.57. The 50-Day Moving Average of the stock is -6.39%, while the 200-Day Moving Average is calculated to be 7.29%.
Shares Statistics:
EW traded an average of 4.05M shares per day over the past three months and 3283140 shares per day over the past ten days. A total of 601.10M shares are outstanding, with a floating share count of 593.08M. Insiders hold about 1.58% of the company’s shares, while institutions hold 82.37% stake in the company. Shares short for EW as of 1713139200 were 7375194 with a Short Ratio of 1.82, compared to 1710460800 on 10450841. Therefore, it implies a Short% of Shares Outstanding of 7375194 and a Short% of Float of 1.24.
Earnings Estimates
Current recommendations for the stock of the company come from 24.0 analysts. On average, analysts expect EPS of $0.69 for the current quarter, with a high estimate of $0.72 and a low estimate of $0.67, while EPS last year was $0.66. The consensus estimate for the next quarter is $0.69, with high estimates of $0.71 and low estimates of $0.66.
Analysts are recommending an EPS of between $2.8 and $2.65 for the fiscal current year, implying an average EPS of $2.76. EPS for the following year is $3.12, with 29.0 analysts recommending between $3.43 and $2.84.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 23 analysts. It ranges from a high estimate of $1.67B to a low estimate of $1.63B. As of the current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.5BFor the next quarter, 23 analysts are estimating revenue of $1.62B. There is a high estimate of $1.65B for the next quarter, whereas the lowest estimate is $1.59B.
A total of 31 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.62B, while the lowest revenue estimate was $6.48B, resulting in an average revenue estimate of $6.56B. In the same quarter a year ago, actual revenue was $6BBased on 31 analysts’ estimates, the company’s revenue will be $7.2B in the next fiscal year. The high estimate is $7.36B and the low estimate is $6.97B.
